Highlights 

  • IMDELLTRA receives full FDA approval for treating extensive-stage small cell lung cancer after platinum-based chemotherapy. 
  • Phase 3 DeLLphi-304 data supported the conversion from accelerated to full approval. 
  • NCCN Guidelines now list tarlatamab as the only Category 1 preferred option for this patient group. 
  • Study showed IMDELLTRA cut the risk of death by 40% over standard chemotherapy. 
  • Median overall survival improved by more than five months in treated patients. 

Amgen (NASDAQ:AMGN) has received full approval from the U.S.Food and Drug Administrationfor IMDELLTRA (tarlatamab-dlle), a targeted therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. This decision upgrades IMDELLTRA’s initial accelerated approval, marking a key advancement for patients facing a challenging and aggressive form of lung cancer. 

The full approval was based on results from the global Phase 3 DeLLphi-304 study, which met its primary endpoint and demonstrated a meaningful clinical improvement over traditional treatment options. The FDA’s decision underscores the therapy’s demonstrated benefit and the growing role of novel biologics in hard-to-treat cancers.

DeLLphi-304 Study Shows Significant Survival Advantage

The DeLLphi-304 trial revealed that IMDELLTRA reduced the risk of death by 40% compared to standard-of-care chemotherapy. Importantly, the therapy extended median overall survival by more than five months, a notable achievement for a cancer type known for rapid progression and limited treatment durability. 

Patients in the trial who had previously progressed after one line of platinum-based chemotherapy saw improved outcomes, positioning IMDELLTRA as a treatment that may offer renewed hope for those with limited options. The data played a central role in securing the therapy’s full approval.

NCCN Guidelines Updated to Reflect Preferred Status

Following the release of the Phase 3 results, the National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology. Tarlatamab was added as the only Category 1 preferred treatment option for adults with ES-SCLC who experienced disease progression after platinum-based chemotherapy. 

This designation highlights the therapy’s clinical relevance and reinforces its place at the forefront of treatment strategies for recurrent ES-SCLC. With this update, clinicians now have a guideline-endorsed option backed by rigorous evidence, potentially shaping treatment pathways across oncology centers. 

Conclusion 

The full FDA approval of Amgen’s IMDELLTRA represents a meaningful development in treating extensive-stage small cell lung cancer, an area where new therapeutic options are urgently needed. Supported by compelling Phase 3 data and recognized by updated NCCN Guidelines, IMDELLTRA may help reshape outcomes for patients who have exhausted standard therapies. As oncology continues to evolve, this approval illustrates the growing impact of precision-engineered treatments in improving survival and care quality. 

Amgens’ shares closed at USD 342.40 on November 19, marking a 0.46% decrease from the prior session.

Also read - Gilead (Nasdaq:GILD) Lenacapavir Arrives in Eswatini and Zambia in Major HIV Prevention Milestone